Table 1.
Patient disposition (N = 88)
| Patient disposition | n (%) |
|---|---|
| Received one or more doses of study treatment | 88 (100.0) |
| Treatment ongoing | 1 (1.1) |
| Off treatment | 87 (98.9) |
| Reason for discontinuation of treatment | 87 (98.9) |
| Adverse event | 11 (12.5) |
| Lost to follow-up | 1 (1.1) |
| Protocol noncompliance | 1 (1.1) |
| Death | 10 (11.4) |
| Disease progression | 45 (51.1) |
| Withdrawal of consent | 9 (10.2) |
| Other | 10 (11.4) |
| Discontinued treatment but still in follow-up | 19 (21.6) |
| Reinitiated treatment with avelumab | 1 (1.1) |
| Discontinued from the trial | 68 (77.3) |
| Lost to follow-up | 3 (3.4) |
| Death | 58 (65.9) |
| Withdrawal of consent | 7 (8.0) |